Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2006-03-28
2006-03-28
Webman, Edward J. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reissue Patent
active
RE039050
ABSTRACT:
A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formulaor a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompassed by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4185108 (1980-01-01), Samour et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 4729999 (1988-03-01), Young
patent: 4894373 (1990-01-01), Young
patent: 4970237 (1990-11-01), Jensen et al.
patent: 5011853 (1991-04-01), Olney
patent: 5075321 (1991-12-01), Schreiber
patent: 5118667 (1992-06-01), Adams
patent: 5208031 (1993-05-01), Kelly
patent: 5393763 (1995-02-01), Black et al.
patent: 5395842 (1995-03-01), Labrie et al.
patent: 5441947 (1995-08-01), Dodge et al.
patent: 5445941 (1995-08-01), Yang
patent: 5457116 (1995-10-01), Black et al.
patent: 5457117 (1995-10-01), Black et al.
patent: 5461065 (1995-10-01), Black et al.
patent: 5462949 (1995-10-01), Jones et al.
patent: 5464845 (1995-11-01), Black et al.
patent: 5468773 (1995-11-01), Dodge et al.
patent: 5472962 (1995-12-01), Koizumi et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5510370 (1996-04-01), Hock
patent: 5534527 (1996-07-01), Black et al.
patent: 5567713 (1996-10-01), Cullinan et al.
patent: 5591753 (1997-01-01), Black et al.
patent: 5610168 (1997-03-01), Draper
patent: 5624940 (1997-04-01), Bryant et al.
patent: 5629425 (1997-05-01), LaBell et al.
patent: 5641790 (1997-06-01), Draper
patent: 5646137 (1997-07-01), Black et al.
patent: 5731327 (1998-03-01), Luke
patent: 5747510 (1998-05-01), Draper
patent: 5811120 (1998-09-01), Gibson et al.
patent: 5972383 (1999-10-01), Gibson et al.
patent: 6087378 (2000-07-01), Cullinan et al.
patent: 6096781 (2000-08-01), Cullinan
patent: 6156786 (2000-12-01), Cullinan
patent: 6395769 (2002-05-01), Cullinan
patent: 6458811 (2002-10-01), Arbuthnot et al.
patent: 6713494 (2004-03-01), Cuff et al.
patent: 2003/0212058 (2003-11-01), Black et al.
patent: 4422193 (1994-02-01), None
patent: 9303013 (1994-02-01), None
patent: 2101356 (1994-01-01), None
patent: 0062505 (1982-10-01), None
patent: 0068563 (1983-01-01), None
patent: 0584952 (1994-03-01), None
patent: 0605193 (1994-07-01), None
patent: 0674903 (1995-10-01), None
patent: 2097788 (1982-11-01), None
patent: 9302163 (1994-07-01), None
patent: 0106450 (1993-11-01), None
patent: 303863 (1994-01-01), None
patent: 304924 (1994-06-01), None
patent: 177348 (1994-02-01), None
patent: WO93/10113 (1993-05-01), None
patent: WO 93/10113 (1993-05-01), None
patent: WO93/1074 (1993-06-01), None
patent: 9305283 (1994-01-01), None
Black et al., “Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;” The Endocrine Society, Abstract 1982.
Black et al., “Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice,” Life Sciences, 26:1980, 1453-1458.
Black et al., “Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors,” Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., “Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms,” Endocrinology 109; 1981, 987-989.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Black et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2(4-methoxypehnyl)-1-napthalenyl][4-[2-pyrrolidinyl)ethoxyl]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22; 1979, 962-966.
Bryant et al., “Raloxifene is a Tissue Specific Estrogen Agonist”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Cypriani B, Tabacik C, Descomps B, Crastes DP A. Role of Estrogen Receptors and Antiestrogen Binding Sites in an Early Effect of Antiestrogens, The Inhibition of Cholesterol Biosynthesis. J. Steroid Biochem 1988;31(5):763-771.
Cypriani B, Tabacik C, Descomps B. Effect on Estradiol and Antiestrogens on Cholesterol Biosynthesis in Hormone-Dependent and Independent Breast Cancer Cell Lines. Biochim. Biophys. Acta, ser Mol. Cell Res 1988:972(2):167-178.
Copending U.S. Appl. No. 10/446,210, filed May 27, 2003, Black et al.
Jordan, VC, Estrogen Antiestrogen action and Breast Cancer Therapy, (excerpts) , pp. 28-30, and 516-517, Nov. 24, 1986.
Black, L. J. “Biological Actions and Binding Properties of a New Estrogen Antagosist LY117018,” In:Hormone Antagonists,129-45, 1982 (M. K. Agarwal ed.) Walter de Gruyter and Co., Berlin N.Y.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Tex., Jun. 8-10, 1983, abs. 93.
Williams, et al., Journal of Bone and Mineral Research, 6 (1991).
Copending U.S. Appl. No. 10/375,339, filed Feb. 27, 2003, Black.
Copending U.S. Appl. No. 10/375,341, filed Feb. 27, 2003, Black et al.
Barr's Paragraph IV Certification (pp. 1-29) and 2 page letter (Oct. 9, 2002) enclosing the same.
Eli Lilly and Company's Supplemental Response To Barr's Interrogatory No. 12 (served on Jun. 28, 2004).
Barr Laboratories' Second Supplemental Responses to Eli Lilly's Interrogatories Nos. 5, 6 and 9 (served on Sep. 20, 2004).
Banks PK, Meyer K, Brodie AM H. Regulation of ovarian steroid biosynthesis by estrogen during proestrus in the rat. Endocrinology 1991;129(3):1295-1304.
Beall, PT, Misra LK, Young RL, Spjut HJ, Evans HJ, Leblanc. Clomiphene Protects Against Osteoporosis in the Mature Ovariectomized Rat. Calcif. Tissue Int., 36: 123-125 (1984).
Black LJ, Masahiko S, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Benach WR, Frolik CA, Tamine JD, Bryant HU. Raloxifene (LY139481 HCl) Prevents Bone Loss and Reduces Serum Cholesterol without Causing Uterine Hypertrophy in Ovariectomized Rats. J. Clin. Invest. Jan. 1994;93:63-69.
Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II Evaluation of LY156758 in metastatic breast cancer. Oncology 1988;45(5):344-345.
Chou Y, Iguchi T, Bern H. Effects of antiestrogens on adult and neonatal mouse reproductive organs. Reprod Toxicol 1992;6(5):439-46.
Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983;32(5):2869-2875.
Daniel CW, Silberstein GB, Strickland P. Direct action of 17beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res 1987;47(22):6052-57.
De Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F. Characteristics of the biphasic action of androgens and of the potent antioproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991;51(19):5165-5170.
Draper MW, Flowers DE, and Huster WJ. Effects of raloxifene (LY 139481) on biochemical markers of bone and lipid metabolism in healthy post-menopausal Women. Abstracts of the Fourth International Symposium on Osteoporosis , Hong Kong 1993.
Draper MW, Flowers DE, Huster WJ, and Neild JA. Effects of raloxifene (LY 139481 HCl) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. Proceedings from the Fourth International Symposium on Osteoporosis, Hong Kong, 1993.
Draper MW, Boss SM, Huster WJ, and Neild JA. Effects of Raloxifene Hydrochloride on Serum Markers of Bone and Lipid Metabolism—Dose-Response Relationships. Abstracts of The First International Conference on Steroids and Bone, Florence, Italy, May 1994, Calcified Tissue Int.54:329-362.
F
Black Larry J.
Draper Michael W.
Eli Lilly and Company
Webman Edward J.
Woodard, Emhardt, Moriarity, McNett & Henry LLP
LandOfFree
Methods of use for inhibiting bone loss and lowering serum... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of use for inhibiting bone loss and lowering serum..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of use for inhibiting bone loss and lowering serum... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594469